Article Text

Download PDFPDF
CP-097 Impact of direct acting antivirals for hepatitis C in antiretroviral therapy in co-infected patients
  1. E Campos-Davila1,
  2. F Téllez-Pérez2,
  3. D Guerra-Estevez3,
  4. JJ Ramos-Báez1,
  5. E Marquez-Fernandez3,
  6. P Villanueva4,
  7. M Perez-Perez2
  1. 1Hospital Sas La Linea, Pharmacy, La Linea de La Concepcion, Spain
  2. 2Campo de Gibraltar HealthCare Area, Infectious Disease Unit, La Línea de La Concepción, Spain
  3. 3Campo de Gibraltar HealthCare Area, Pharmacy, La Línea de La Concepción, Spain
  4. 4Campo de Gibraltar HealthCare Area, Pharmacy, Algeciras, Spain


Background When both HIV and hepatitis C virus (HCV) treatments are indicated, the antiretroviral therapy (ART) may need to be modified before HCV treatment is initiated to reduce the potential for drug-drug interactions and overlapping toxicities that may develop during the period of concurrent treatment.

Purpose To describe the modifications on ART when HIV/HCV co-infected patients start HCV therapy with new direct acting antivirals (DAA) in our healthcare area and evaluate its economic impact on ART regimen costs.

Material and methods Observational, retrospective study. Gender, ART regimen and its cost per month (previous/after starting HCV therapy) and HCV regimen chosen were recorded for every HIV/HCV co-infected patient who started therapy with new DAA agents (simeprevir, sofosbuvir, ledipasvir, daclatasvir, ombitasvir/paritaprevir/ritonavir and dasabuvir).

Patient data, regimens prescribed and treatment cost were collected from external patients and management pharmacy´s database and analysed using the SPSS statistical package.

Results 47 patients (15% female) started therapy with DAA agents during the time of the study. ART was modified in 26 (55.3%) patients.

27 antiretroviral drugs were changed (in 1 patient, two modifications were needed), 12 (44.4%) due to the substitution of one non-nucleoside reverse transcriptase inhibitor (NNRTI) and the other 15 (55.6%) corresponded to a change in a protease inhibitor (PI) of the original regimen. The modifications from a NNRTI to avoid interactions with DAAs resulted in the prescription of another not contraindicated NNRTI (rilpivirine) in 8 (66.7%) cases, an integrase strand transfer inhibitor (INSTI) in 3 (25%) and a PI (darunavir/r) in 1 case (8.3%). The modifications from an original PI resulted in the replacement by another not contraindicated PI in 5 patients, to an INSTI in 5 and to a NNRTI in another 5 (33.3% each).

The average ART cost per patient was 632.68€ monthly before starting HCV therapy, and 667.40€ later (variations from -169.73€ to +388.67€), which means an increase of 5.5% in the monthly cost per patient.

Conclusion Original ART had to be modified in a high proportion of patients (more than half in our series) when starting HCV therapy. All modifications were due to NNRTI and PI interactions with current DAA agents. These changes have led to a slight increase in the ART cost per patient, which can be considered acceptable for public spending.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.